8月13日，派格生物医药-B盘中上涨8.82%，报6.725港元，成交额8605.05万港元。
消息面上，公司核心产品派达康近期在全国多家医疗机构及线上渠道开出首批商业化处方，触发第二笔约4900万港元里程碑付款，连同此前已收取的6100万港元，累计已收及触发权益金约1.1亿港元。此外，公司此前与Rani Therapeutics签署谅解备忘录推进口服制剂开发，与阿里健康、腾瑞制药签署战略合作打通线上线下商业化链路，维培那肽注射液亦已通过国家医保目录调整初步形式审查，多重利好叠加推动市场对公司商业化放量预期持续升温。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.